Companies covered: COMPASS Pathways PLC (NASDAQ:CMPS), Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), GH Research PLC (NASDAQ:GHRS), Cybin Inc. (NYSEAMERICAN:CYBN), ATAI Life Sciences NV (NASDAQ:ATAI), BetterLife Pharma Inc. (OTCMKTS:BETRF), Cansortium Inc. (OTCMKTS:CNTMF), Greenlane Holdings Inc. (NASDAQ:GNLN), Planet 13 Holdings Inc. (OTCMKTS:PLNH)
Companies covered: Achieve Life Sciences (NASDAQ:ACHV), Pfizer, Inc. (NYSE:PFE), Biora Therapeutics Inc. (NASDAQ:BIOR), Rani Therapeutics Holdings Inc. (NASDAQ:RANI), Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX), Novo Nordisk A/S (NYSE:NVO), Catalent, Inc. (NYSE:CTLT), Gilead Sciences, Inc. (NASDAQ:GILD), Merck & Company, Inc. (NYSE:MRK), Bristol-Myers Squibb Company (NYSE:BMY), AstraZeneca PLC (NASDAQ:AZN), Eli Lilly and Company (NYSE:LLY), XOMA Corporation (NASDAQ:XOMA), Fortress Biotech, Inc. (NASDAQ:FBIO), Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), Lexaria Bioscience Corp. (NASDAQ:LEXX), Telix Pharmaceuticals Ltd. (OTCMKTS:TLPPF), IN8bio, Inc. (NASDAQ:INAB), DRI Healthcare Trust (OTCMKTS:DHTRF), Royalty Pharma plc (NASDAQ:RPRX), Argenx SE (ADR) (NASDAQ:ARGX), Amgen Inc. (NASDAQ:AMGN), Genmab A/S - ADR (NASDAQ:GMAB), Johnson & Johnson (NYSE:JNJ), Novartis AG (NYSE:NVS), Sanofi (NYSE:SNY), Lantheus Holdings Inc. (NASDAQ:LNTH), Janux Therapeutics Inc. (NASDAQ:JANX)), Cullinan Therapeutics Inc. (NASDAQ:CGEM), NewAmsterdam Pharma Company NV (NASDAQ:NAMS), PTC Therapeutics, Inc. (NASDAQ:PTCT), Dianthus Therapeutics Inc. (NASDAQ:DNTH), Axsome Therapeutics (NASDAQ:AXSM), Longboard Pharmaceuticals Inc. (NASDAQ:LBPH), Praxis Precision Medicines Inc. (NASDAQ:PRAX), Cidara Therapeutics Inc. (NASDAQ:CDTX), Omeros Corporation (NASDAQ:OMER), 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP), CompuMed Inc. (OTCMKTS:CMPD), MediWound Ltd. (NASDAQ:MDWD), Mesoblast Limited (NASDAQ:MESO), NanoViricides, Inc. (NYSEAMERICAN:NNVC), Neuren Pharmaceuticals Ltd. (OTCMKTS:NURPF), OSE Immunotherapeutics SA (EPA:OSE), Pasithea Therapeutics Corp. (NASDAQ:KTTA), Premier, Inc. (NASDAQ:PINC)
Companies covered: InspireMD, Inc. (AMEX:NSPR), Envoy Medical Inc. (NASDAQ:COCH), NeuroPace Inc. (NASDAQ:NPCE), Stereotaxis, Inc. (NASDAQ:STXS), EDAP TMS S.A. (NASDAQ:EDAP), Boston Scientific Corporation (NYSE:BSX), Abbott Laboratories (NYSE:ABT), Johnson & Johnson (NYSE:JNJ), Silk Road Medical Inc. (NASDAQ:SILK), LENSAR Inc. (NASDAQ:LNSR), Tela Bio Inc. (NASDAQ:TELA), Elutia Inc. (NASDAQ:ELUT), Medtronic, Inc. (NYSE:MDT), iRadimed Corporation (NASDAQ:IRMD), Intuitive Surgical, Inc. (NASDAQ:ISRG), Stryker Corporation (NYSE:SYK), Alcon AG (NYSE:ALC), GE HealthCare Technologies Inc. (NASDAQ:GEHC), Hologic, Inc. (NASDAQ:HOLX), RxSight Inc. (NASDAQ:RXST), Glaukos Corp (NYSE:GKOS), Penumbra Inc. (NYSE:PEN), Globus Medical, Inc. (NYSE:GMED), Alphatec Holdings, Inc. (NASDAQ:ATEC), Tempus AI Inc. (NASDAQ:TEM), Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), Zimmer Biomet Holdings Inc. (NYSE:ZBH), DexCom, Inc. (NASDAQ:DXCM), Ekso Bionics Holdings Inc. (NASDAQ:EKSO), OraSure Technologies, Inc. (NASDAQ:OSUR), Sensus Healthcare (NASDAQ:SRTS), Xtant Medical Holdings Inc. (NYSEAMERICAN:XTNT)
Companies covered: Novo Nordisk A/S (NYSE:NVO), Eli Lilly and Company (NYSE:LLY), Amgen Inc. (NASDAQ:AMGN), Merck & Company, Inc. (NYSE:MRK), Roche Holdings Ltd. (ADR) (OTCMKTS:RHHBY), Moderna (NASDAQ:MRNA), BioNTech SE (ADR) (NASDAQ:BNTX), Bristol-Myers Squibb Company (NYSE:BMY), Novartis AG (NYSE:NVS), Cabaletta Bio Inc. (NASDAQ:CABA), Kyverna Therapeutics Inc. (NASDAQ:KYTX), Pfizer, Inc. (NYSE:PFE), Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), AbbVie Inc. (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Altimmune Inc. (NASDAQ:ALT), Aerovate Therapeutics Inc. (NASDAQ:AVTE), Madrigal Pharmaceuticals (NASDAQ:MDGL), Akero Therapeutics Inc. (NASDAQ:AKRO), 89bio Inc. (NASDAQ:ETNB), Insmed, Inc. (NASDAQ:INSM), Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Intellia Therapeutics Inc. (NASDAQ:NTLA), CRISPR Therapeutics AG (NASDAQ:CRSP), Editas Medicine (NASDAQ:EDIT), Immunome Inc. (NASDAQ:IMNM), Disc Medicine Inc. (NASDAQ:IRON), Apogee Therapeutics Inc. (NASDAQ:APGE), ORIC Pharmaceuticals Inc. (NASDAQ:ORIC), TScan Therapeutics Inc. (NASDAQ:TCRX), Nuvalent Inc. (NASDAQ:NUVL), Inozyme Pharma Inc. (NASDAQ:INZY), Beam Therapeutics Inc. (NASDAQ:BEAM), Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), Scholar Rock Holding Corp. (NASDAQ:SRRK), y-mAbs Therapeutics Inc. (NASDAQ:YMAB), Abivax SA (NASDAQ:ABVX), BioVie Inc. (NASDAQ:BIVI), Equillium Inc. (NASDAQ:EQ), Organovo Holdings, Inc. (NASDAQ:ONVO), PDS Biotechnology Corporation (NASDAQ:PDSB)
Companies covered: Achieve Life Sciences (NASDAQ:ACHV), BioLineRx Ltd. (NASDAQ:BLRX), Biora Therapeutics Inc. (NASDAQ:BIOR), Bluejay Diagnostics Inc. (NASDAQ:BJDX), BriaCell Therapeutics Corp. (NASDAQ:BCTX), Pfizer, Inc. (NYSE:PFE), AbbVie Inc. (NYSE:ABBV), Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX), Tenax Therapeutics, Inc. (NASDAQ:TENX), United Therapeutics Corporation (NASDAQ:UTHR), Merck & Company, Inc. (NYSE:MRK), GlaxoSmithKline PLC (NYSE:GSK), Moderna (NASDAQ:MRNA), Johnson & Johnson (NYSE:JNJ), Kenvue Inc. (NYSE:KVUE), Omeros Corporation (NASDAQ:OMER), InflaRx NV (NASDAQ:IFRX), Agilon Health Inc. (NYSE:AGL), BioVie Inc. (NASDAQ:BIVI), Elutia Inc. (NASDAQ:ELUT), Inozyme Pharma Inc. (NASDAQ:INZY), PDS Biotechnology Corporation (NASDAQ:PDSB), SELLAS Life Sciences Group Inc. (NASDAQ:SLS), Theravance Biopharma, Inc. (NASDAQ:TBPH), Virpax Pharmaceuticals Inc. (NASDAQ:VRPX)
